First-Line Treatment for Posner-Schlossman Syndrome: Reducing Intraocular Pressure and Inflammation

This protocol covers the structured first-line management of Posner-Schlossman syndrome, addressing the need to lower elevated intraocular pressure and control inflammation in the affected eye.

The clinical priority is combined anti-inflammatory and intraocular pressure-lowering therapy directed at the affected eye, with a defined reassessment point to guide any subsequent adjustment.

Treatment Approach

Partial overview — full regimen in the protocol

The first-line approach involves topical anti-inflammatory and anti-hypertensive therapy applied to the affected eye. The regimen includes a structured step guided by the pressure response. Full details — including the complete sequence, agents, and duration — are available in the protocol.

Treatment goals: Reduction of intraocular pressure in the affected eye and reduction of intraocular inflammation, reassessed at approximately one week.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/j.1444-0938.2006.00088.x

anti-hypertensive and anti-inflammatory treatment is indicated to reduce IOP and inflammation.
Treatment was instituted for the right eye with fluorometholone 0.1% qid and brimonidine 0.2% bid.
One week later, pressures had fallen to R 12 mmHg, L 20 mmHg.
Brimonidine was discontinued and the steroid tapered.

View source ↗